Abstract:Multidrug-resistance (MDR) featuring complicated and poorly defined mechanisms is a major obstacle to the success of cancer chemotherapy in the clinic. Compound nanoparticles comprising multiple cytostatics with different mechanisms of action are commonly developed to tackle the multifaceted nature of clinical MDR. However, the different pharmacokinetics and release profiles of various drugs result in inconsistent drug internalization and suboptimal drug synergy at the tumor sites. In the present study, a type of self-targeting hyaluronate (HA) nanogels (CDDPHANG/DOX) to reverse drug resistance through the synchronized pharmacokinetics, intratumoral distribution, and intracellular release of topoisomerase II inhibitor doxorubicin (DOX) and DNA-crosslinking agent cisplatin (CDDP) is developed. With prolonged circulation time and enhanced intratumoral accumulation in vivo, CDDPHANG/DOX shows efficient drug delivery into the drug-resistant MCF-7/ADR breast cancer cells and enhanced antitumor activity. Besides, fluorescence imaging of DOX combined with the micro-computed tomography (micro-CT) imaging of CDDP facilitates the visualization of this combination tumor chemotherapy. With visualizable synchronized drug delivery, the self-targeting in situ crosslinked nanoplatform may hold good potential in future clinical therapy of advanced cancers.

What problem does this paper attempt to address?

This paper aims to solve the main obstacles in the treatment of multi - drug - resistant (MDR) breast cancer. Multi - drug - resistance is a complex mechanism that leads to a decrease in the accumulation of chemotherapy drugs in tumor cells, thereby reducing the treatment effect. Specifically, the paper developed a self - targeting hyaluronic acid nanogel (CDDPHANG/DOX) for the synchronous release of the topoisomerase II inhibitor doxorubicin (DOX) and the DNA - cross - linking agent cisplatin (CDDP) to overcome the treatment challenges of multi - drug - resistant breast cancer. ### Main problems 1. **Multi - drug - resistance (MDR)**: - Multi - drug - resistance is the main obstacle to the success of clinical chemotherapy, and its mechanism is complex and unclear. - The common solution is to use composite nanoparticles containing multiple cytotoxic drugs with different mechanisms of action. However, the pharmacokinetics and release characteristics of different drugs are inconsistent, resulting in poor absorption and synergy of drugs at the tumor site. 2. **Inconsistency in drug release**: - Differences in the pharmacokinetics and release characteristics of different drugs lead to inconsistent absorption of drugs at the tumor site, affecting the synergy of drugs. - Especially in multi - drug - resistant cells, the internalization and sensitivity of drugs are reduced, further exacerbating the treatment difficulty. ### Solutions - **Self - targeting hyaluronic acid nanogel (CDDPHANG/DOX)**: - Through the specific binding of hyaluronic acid (HA) to the CD44 receptor on the surface of tumor cells, targeted delivery to tumor cells is achieved. - Doxorubicin (DOX) and cisplatin (CDDP) inside the nanogel form a stable structure through coordinated interactions, avoiding premature leakage during the circulation process. - In the acidic environment inside tumor cells, the nanogel disintegrates, achieving the synchronous release of DOX and CDDP, thereby maximizing the internalization and retention of drugs at the tumor site and reversing the acquired chemotherapy resistance. ### Experimental results - **Pharmacokinetics and tissue distribution**: - CDDPHANG/DOX exhibits a longer blood circulation time and a higher plasma concentration, prolonging the residence time of drugs in the body. - Through fluorescence imaging and micro - computer tomography (micro - CT) imaging, the effective accumulation and release of drugs at the tumor site are verified. - **Cell uptake and proliferation inhibition**: - The uptake of CDDPHANG/DOX in multi - drug - resistant breast cancer cells (MCF - 7/ADR) is significantly higher than that of free drugs, and it can effectively inhibit cell proliferation. - The results of fluorescence microscopy and flow cytometry show that the accumulation and release behavior of CDDPHANG/DOX in cells are better than those of free drugs. ### Conclusion By developing the self - targeting hyaluronic acid nanogel (CDDPHANG/DOX), the paper has successfully solved the main problems in the treatment of multi - drug - resistant breast cancer, achieved the synchronous release of doxorubicin (DOX) and cisplatin (CDDP), improved the accumulation and synergy of drugs at the tumor site, and provided a new strategy for future clinical treatment.

Self-targeting visualizable hyaluronate nanogel for synchronized intracellular release of doxorubicin and cisplatin in combating multidrug-resistant breast cancer

Regulation of Ca2+ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail

Polymer-lipid Hybrid Nanoparticles Synchronize Pharmacokinetics of Co-Encapsulated Doxorubicin-Mitomycin C and Enable Their Spatiotemporal Co-Delivery and Local Bioavailability in Breast Tumor.

Dual-responsive Mpeg-Plga-pglu Hybrid-Core Nanoparticles with a High Drug Loading to Reverse the Multidrug Resistance of Breast Cancer: an in Vitro and in Vivo Evaluation.

Synergistic Cisplatin/Doxorubicin Combination Chemotherapy for Multidrug-Resistant Cancer Via Polymeric Nanogels Targeting Delivery.

Polymeric nanovesicle as simultaneous delivery platform with Doxorubicin conjugation and Elacridar encapsulation for enhanced treatment of multidrug-resistant breast cancer

Mitochondrial Targeted Doxorubicin Derivatives Delivered by ROS-responsive Nanocarriers to Breast Tumor for Overcoming of Multidrug Resistance.

pH-/Redox-Responsive Nanodroplet Combined with Ultrasound-Targeted Microbubble Destruction for the Targeted Treatment of Drug-Resistant Triple Negative Breast Cancer

Trackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance

Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.

A dual-responsive hyaluronic acid nanocomposite hydrogel drug delivery system for overcoming multiple drug resistance

Injectable And Self-Healing Thermosensitive Magnetic Hydrogel For Asynchronous Control Release Of Doxorubicin And Docetaxel To Treat Triple-Negative Breast Cancer

Delivery of Mitochondriotropic Doxorubicin Derivatives Using Self-Assembling Hyaluronic Acid Nanocarriers in Doxorubicin-Resistant Breast Cancer

Multifunctional nanogel engineering with redox-responsive and AIEgen features for the targeted delivery of doxorubicin hydrochloride with enhanced antitumor efficiency and real-time intracellular imaging

Versatile hydrogel drug carrier loading with peptide-carbon dots conjugates for efficient targeting and synergistic suppression of breast cancer cell

Co-delivery of DOX and PDTC by Ph-Sensitive Nanoparticles to Overcome Multidrug Resistance in Breast Cancer.

Rational Design of Multifunctional Polymeric Micelles with Stimuli-Responsive for Imaging-Guided Combination Cancer Therapy

Water-Responsive Hybrid Nanoparticles Codelivering ICG and DOX Effectively Treat Breast Cancer via Hyperthermia-aided DOX Functionality and Drug Penetration.

Tumor-Triggered Drug Release with Tumor-Targeted Accumulation and Elevated Drug Retention To Overcome Multidrug Resistance

Sequential thermo-induced self-gelation and acid-triggered self-release process of drug-conjugated nanoparticles: A strategy for the sustained and controlled drug delivery to tumors

Synergistic Combination of Bioactive Hydroxyapatite Nanoparticles and the Chemotherapeutic Doxorubicin to Overcome Tumor Multidrug Resistance.